
    
      This is a prospective randomized non-comparative multicenter open label trial of induction
      therapy with LAmB for DH in AIDS patients, followed by oral therapy with itraconazole.

      The sample size planned is 99 patients of both sexes, older than 18 years (33 patients per
      study arm), infected with HIV and with confirmed diagnosis for DH. This sample size considers
      10% of dropout.

      The study will be conducted in accordance with the Helsinki Declaration, as well as the
      Standards national and international Guidelines for Good Clinical Practices.

      Eight research centres in Brazil will competitively recruit patients: Santa Casa de
      Misericórdia de Porto Alegre (Porto Alegre; Dr Alessandro C. Pasqualotto), Hospital de
      Clínicas de Porto Alegre (Porto Alegre; Dr Diego R. Falci), Hospital Nossa Senhora da
      Conceição (Porto Alegre; Dr Marineide Melo), Hospital de Doenças Tropicais (Goiânia; Dr
      Cassia S. de Miranda Godoy), Hospital São José de Doenças Infecciosas (Fortaleza; Dr
      Terezinha M. J. Silva Leitão), and Hospital Giselda Trigueiro (Natal, Dr Monica B. Bay),
      Hospital Universitário Osvaldo Cruz (Recife, Dr. Filipe Prohaska Batista) e Instituto de
      Infectologia Emília Ribas (São Paulo, Dr. José Ernesto Vidal Bermudez).

      AIDS patients with DH will be randomized to one of three study arms:

      (i) single IV dose of 10 mg/kg of L-AmB; (ii) single IV dose of 10 mg/kg of L-AmB on day 1,
      followed by 5 mg/kg of L-AmB on day 3; (iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.

      Induction therapy will be followed in all patients by oral therapy with itraconazole capsules
      at 400 mg/daily for a year, azole drug which is already therapy of choice for consolidation
      of histoplasmosis, according to national and international Guidelines.
    
  